N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
| Title | Journal |
|---|---|
| L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20161001 |
| Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers. | Journal of medicinal chemistry 20160728 |
| Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. | Therapeutic advances in respiratory disease 20160401 |
| Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20160401 |
| Osimertinib: First Global Approval. | Drugs 20160201 |
| Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. | Journal of hematology & oncology 20160101 |
| Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. | Journal of structural biology 20151201 |
| Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. | JAMA oncology 20151001 |
| Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20150901 |
| Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. | The Lancet. Oncology 20150901 |
| The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). | Annals of translational medicine 20150501 |
| Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. | Current opinion in oncology 20150301 |
| Dacomitinib in lung cancer: a 'lost generation' EGFR tyrosine-kinase inhibitor from a bygone era? | Drug design, development and therapy 20150101 |
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. | Cancer discovery 20140901 |
| Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. | Journal of the National Comprehensive Cancer Network : JNCCN 20130201 |
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. | The New England journal of medicine 20040520 |